More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

Noxopharm Receives A$5.865M R & D Tax Rebate

Jan 6, 2022 at 10:37 PM EST · Issued by Noxopharm Ltd.

Filed with ASX · Jan 6, 2022 at 10:37 PM EST · 2 pages · English

On 6ix: 6ix.com/news/noxopharm-receives-adollar5.865m-r-and-d-tax-rebate

Noxopharm Ltd. on 6ix

Story so far

  • Noxopharm Receives A$4.59M Federal Gov R&D Tax RebateMar 2, 2021
  • NOX Receives FY19 Federal Government R&D Tax RebateAug 23, 2019

Earlier from Noxopharm

  • Noxopharm Announces Leadership TransitionJan 4, 2022
  • Noxopharm DARRT-2 Cancer Trial UpdateDec 13, 2021
  • Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical ResearchDec 1, 2021
  • Licencing Deal Expands Noxopharm Drug OpportunitiesNov 16, 2021
  • Retraction of Grant AnnouncementNov 16, 2021

Later from Noxopharm

  • December 2021 Quarterly Activities Report and Appendix 4CJan 26, 2022
  • Appendix 4D and Half Year 2022 Financial ReportFeb 21, 2022
  • First Patient Treated in CEP-2 Sarcoma TrialFeb 27, 2022
  • Orphan Drug Designation Granted to Noxopharm by US FDAMar 21, 2022
  • FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma TreatmentMar 29, 2022
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer